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Considering that the non-classical HLA-G molecule has well-recognized tolerogenic prop-
erties, HLA-G expression is expected to be deleterious when present in tumor cells and in
cells chronically infected by viruses, whereas HLA-G expression is expected to be advan-
tageous in autoimmune disorders. The expression of HLA-G on tissue or peripheral blood
cells, the levels of soluble HLA-G and polymorphic sites along the gene have been studied
in several disorders. In this study, we revised the role of the molecule and polymorphic
sites along the HLA-G gene in tumors, viral hepatitis, and parasitic disorders. Overall, sev-
eral lines of evidence clearly show that the induction of HLA-G expression in tumors has
been associated with worse disease outcome and disease spread. In addition, the few
studies conducted on hepatitis and parasitic disorders indicate that HLA-G may contribute
to disease pathogenesis. Few isolated polymorphic sites, primarily located at the coding
or 3′ untranslated HLA-G region, have been evaluated in these disorders, and a complete
HLA-G typing together with the study of gene regulatory elements may further help on
the understanding of the influence of the genetic background on disease susceptibility.
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INTRODUCTION
HLA-G is a non-classical class I gene of the human Major
Histocompatility Complex (NCBI gene ID: 3135), presenting a
restricted tissue expression pattern and encoding molecules with
immune modulatory properties. This gene, firstly described by
Geraghty and colleagues in 1987 (1), presents a genetic struc-
ture that resembles other classical HLA class I genes. However,
contrary to that observed for classical class I genes (HLA-A,
-B, and -C), the HLA-G gene is quite conserved among dif-
ferent populations and within the same population, present-
ing only a few non-synonymous mutations and several varia-
tion sites characterized as synonymous modifications, intronic
variations, or variable sites at the regulatory regions [reviewed
at Ref. (2)].
HLA-G does not seem to initiate immune responses as its
classical counterparts. Instead, the HLA-G molecule is associated
with the induction of inhibitory stimuli for T and B lymphocytes
(3, 4), Natural Killer (NK) cells (3), and antigen-presenting cells
(APC) (5). The HLA-G molecule may directly interact with mul-
tiple inhibitory receptors, including ILT2/CD85j/LILRB1 (ILT2),
ILT4/CD85d/LILRB2 (ILT4), and KIR2DL4/CD158d (KIR2DL4).
The HLA-G molecule was firstly detected at the trophoblast
in the maternal fetal interface, probably modulating the maternal
immune system during pregnancy. Beyond trophoblast expres-
sion, HLA-G has been detected in few normal tissues, including
cornea (6), thymus (7), and erythroid and endothelial precursors
(8), and its upregulation has been detected in several pathological
conditions as described in the present review.
Alternative splicing is also an important characteristic of the
HLA-G gene. It may produce at least seven protein isoforms gen-
erated by alternative splicing of the primary transcript [reviewed
at Ref. (2)], in which four isoforms are membrane-bound and
three isoforms are soluble due to the lack of a transmembrane
domain.
Much effort has been made to evaluate HLA-G worldwide
variability. The HLA-G gene seems to present functional poly-
morphisms mainly in the regulatory regions, probably influencing
its expression. Considering data from at least 18 different popu-
lations (9–12) the HLA-G locus presents few frequent extended
haplotypes. These haplotypes are a combination among a small
number of very divergent promoter and 3′ untranslated region
(3′UTR) haplotypes (Figures 1 and 2), and a coding allele usually
encodes the same HLA-G molecule (Figure 3). The regulatory seg-
ments are characterized by the occurrence of several polymorphic
sites presenting high heterozygosis. Although there is no consensus
regarding where the HLA-G transcription starts (13), the polymor-
phisms at the 5′ upstream regulatory region (5′URR) have been
considered to influence HLA-G expression, mainly because of the
fact that polymorphic sites coincides with, or are close to, known
transcription factor binding sites (Figure 1) [Reviewed at Ref.
(13)]. Likewise, haplotypes at the HLA-G 3′UTR segment have
been considered influencing HLA-G expression, mainly because
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FIGURE 1 | Variation sites at the 5′ upstream regulatory region
(5′URR) of the HLA-G gene (1.4 kb upstream of ATG), as well as the
target binding sites of the described transcriptional factors. The
position of the variation sites is determined in relation to Adenine of the
initiation codon ATG. *Since there is no official nomenclature for 5′URR
haplotypes, they were designed as previously reported (10). Transcription
factors: CREB1, CAMP responsive element binding protein 1; ATF1, cyclic
AMP-dependent transcription factor ATF-1; RREB1, Ras responsive
element binding protein 1; IRF1, interferon regulatory factor 1; p50,
nuclear factor NF-κ-B p105 subunit; RFX5, DNA-binding protein RFX5 (RFX
family); PR, progesterone receptor. I, insertion of a guanine at position
−540; ∆, deletion of an adenine at position −533.
FIGURE 2 | Variation sites at the 3′ untranslated region (3′UTR) of the
HLA-G gene that may influence HLA-G expression. Polymorphic sites
associated with diseases presented in this review are underlined. Arrows
indicate polymorphic sites that have been functionally studied. *Since there is
no official nomenclature for 3′UTR haplotypes, they were designed as
previously reported (11). DEL, deletion; INS, insertion.
the fact that some polymorphic sites (such as the one at position
+3142) may influence the binding of specific microRNAs (14–
17) or may influence mRNA stability (such as the one at position
+3187) and alternative splicing (such as the 14-bp polymorphism)
(Figure 2).
The HLA-G coding region presents mainly synonymous or
intronic variation sites. Considering the most frequent HLA-G
coding haplotypes found worldwide [reviewed at Ref. (2, 18)],
only five different HLA-G full-length molecules are frequently
found, in which four are complete molecules encoded by the HLA-
G-*01:01, *01:03, *01:04, and *01:06 allele groups, and one is a
truncated molecule encoded by the HLA-G*01:05N null allele.
Although some different HLA-G molecules were detected world-
wide, they are usually quite rare and the same HLA-G coding
alleles are usually detected in every population studied so far.
Apparently, all these frequently found molecules (exception made
to the G*01:05N) present the same modulatory effects described
earlier (2). Considering that only a few extended haplotypes are
usually found, and considering that most of the HLA-G coding
alleles are associated with only one promoter or 3′UTR haplotype,
it is possible that most of the associations described so far regard-
ing HLA-G coding polymorphism and pathological conditions are
reflecting the presence of specific promoter and 3′UTR sequences
and specific HLA-G production capabilities.
In the present review, we report some diseases that have been
associated with the modulation of the HLA-G expression, with
the presence of specific HLA-G gene variation sites or both, and
whenever known, the mechanisms underlying such associations
are discussed.
TUMORS
The arisen of transformed cells and the spread of cancer cell clones
are usually controlled by the immune system cells, particularly
by the action of cytototoxic T and NK cells; however, cancer
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FIGURE 3 | Variation sites at the coding region of the HLA-G gene
from exon 1–4. Polymorphic sites associated with diseases presented in
this review are underlined. *Haplotypes presenting a global frequency
higher than 1% in worldwide populations. Amino acids: A, alanine; S,
serine; F, phenylalanine; Y, tyrosine; T, threonine; M, methionine; Q,
glutamine; R, arginine; E, glutamic acid; P, proline; H, histidine; G,
glycine; D, aspartic acid; V, valine; C, cysteine; L, leucine; I, isoleucine;
W, tryptophan. ∆, deletion.
cells have developed several strategies to evade host immune sur-
veillance. Since classical histocompatibility (HLA-A, -B, and -C)
molecules present tumor antigens to cytotoxic T cells, tumor cells
have developed strategies to escape the cytotoxic effect of T cells by
interfering with the expression of these molecules on tumor cell
surface. On the other hand, the absence of HLA classical molecules
on the surface of tumor cells triggers NK cell activity to elimi-
nate neoplastic cells. If tumor cell expresses HLA-G, the cytotoxic
activity of both T and NK cells are inhibited, facilitating tumor cell
spread. When the decreased expression of classical HLA molecules
is accompanied by an increased expression of immunomodula-
tory molecules such as HLA-G, the effective cytototoxic immune
response against tumor cells is much impoverished [reviewed at
Ref. (2)].
Although the study of HLA-G expression in tumor cells has
been widely explored [reviewed at Ref. (19–21)], the evaluation
of the HLA-G gene polymorphic sites has not been studied at the
same extent, and even rarer are the studies evaluating the relation-
ship between HLA-G tumor expression and HLA-G polymorphic
sites. Next, we highlight some peculiarities of tumors, for which
HLA-G expression (tissue or soluble levels), gene polymorphisms,
or both have been evaluated.
HLA-G EXPRESSION IN TUMORS
Increased HLA-G expression has been observed in different
tumor types, including breast cancer (22–29), hepatocellular car-
cinoma (30–33), papillary thyroid carcinoma (34, 35), follicular
thyroid carcinoma (35), follicular adenoma (35), nasopharyn-
geal carcinoma (36), neuroblastoma (37), bladder transitional
cell carcinoma (TCC) (38), melanoma (39–42), colorectal can-
cer (43–45), gastric cancer (46–48), esophageal carcinoma (49–
53), lung cancer (49, 54–57), renal cell carcinoma (58–62),
glioblastoma (63–66), acute myeloid leukemia (67, 68), and B-
cell chronic lymphocytic leukemia (69–73). Table 1 summarizes
the HLA-G expression in many types of tumors described in this
review.
In most tumors, the increased HLA-G expression has been
associated with advanced disease stages, shorter survival time,
presence of metastasis, higher tumor grade, weak host immune
response, greater tumor size, tumor recurrence, tumor invasion,
poor histological grade, lower classical HLA antigen expression,
presence of infiltrating T regulatory cells, cancer progression,
increased inflammatory cell lesion infiltration, and tumor differ-
entiation (23, 24, 26, 29–32, 34–36, 40–42, 44, 46–48, 50–54, 56,
57, 66, 69, 72, 73, 79). In other tumors, no association between
increased HLA-G expression and clinicopathological features has
been observed, including bladder TCC (38) and acute myeloid
leukemia (67, 68).
Furthermore, increased sHLA-G levels have been reported for
breast cancer (23–25, 75), hepatocellular carcinoma (31–33), pap-
illary thyroid carcinoma (76), neuroblastoma (37), melanoma
(39), colorectal cancer (49, 77), gastric cancer (47, 49), esophageal
carcinoma (49–51), lung cancer (49, 54, 55), renal cell carcinoma
(62), and acute myeloid leukemia (78). Higher sHLA-G levels have
been associated with: (i) increased number of CD4+ regulatory T
(Treg) cells in breast cancer (23), (ii) more aggressive tumor behav-
ior in papillary thyroid carcinoma (76), (iii) local or disseminated
relapse in neuroblastoma (37), (iv) advanced stages of disease and
tumor load in melanoma (39), (v) higher IL-10 production in
esophageal carcinoma (51), (vi) absence of anterior myelodyspla-
sia along with higher leukocytosis in acute myeloid leukemia (78),
and (vii) shorter survival time, high-grade tumors, higher IL-10
production, and loss of HLA classical class I molecules in patients
with lung cancer (54–56).
Interestingly, sHLA-G levels were significantly decreased in
breast cancer patients at 6 and 12 months after surgery (25). In
addition, no association between higher sHLA-G levels and clini-
copathological features has been observed in hepatocellular carci-
noma (33), colorectal cancer (77), gastric cancer (47), esophageal
carcinoma (50, 51), and renal cell carcinoma (62). On the other
hand, plasma sHLA-G levels were closely similar when bladder
TCC patients and healthy controls were compared (38).
Overall, several laboratory (increased HLA-G tumor expres-
sion, increased sHLA-G levels, increased levels of IL-10, and a
cytokine that induces HLA-G expression) and clinical (advanced
disease stages, worse prognosis, and presence of metastasis)
findings do corroborate the malefic role of HLA-G in cancer
disorders.
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Table 1 | Association between HLA-G expression and tumors.
Tumor HLA-G molecule Reference
n Expression (%) Metastasisa sHLA-G (n)
Breast cancer 36 36IHC nd nd (22)
46/39 26(E)IHC/41(S)IHC No nd (74)
58 70.7IHC nd ↑(92)ELISA (23)
235 66IHC Yes ↑(44)ELISA (24)
677 60IHC No nd (27)
nd nd nd ↑(45)ELISA (25)
38 58IHC nd nd (28)
nd nd nd ↑(120)ELISA (75)
52 59.6IHC No nd (29)
45 62IHC Yes nd (26)
Hepatocellular carcinoma 173 57IHC nd nd (30)
219 50.2IHC nd ↑(19)ELISA (31)
36 66.7WB nd ↑(36)ELISA (32)
nd nd nd ↑(80)ELISA (33)
Thyroid cancer nd nd nd ↑(183)ELISA (76)
70 44.3IHC Yes nd (34)
72 77.5IHC No nd (35)
Nasopharyngeal carcinoma 552 79.2IHC Yes nd (36)
Neuroblastoma 12 0IHC nd ↑(53)ELISA (37)
Bladder transitional cell carcinoma 75 68IHC nd Ø(15)ELISA (38)
Melanoma nd nd nd ↑(190)ELISA (39)
79 28IHC nd nd (40)
35 34.2IHC nd nd (42)
Colorectal cancer 39 87RT-PCR nd nd (43)
201 64.6IHC Yes nd (44)
nd nd nd ↑(144)ELISA (77)
nd nd nd ↑(37)ELISA (49)
251 20.3IHC nd nd (45)
Gastric cancer 160 71IHC Yes nd (46)
179 49.7IHC Yes ↑(179)ELISA (47)
nd nd nd ↑(28)ELISA (49)
52 31IHC Yes nd (48)
Esophageal carcinoma 121 90.9IHC Yes nd (52)
79 65.8IHC nd ↑(41)ELISA (50)
nd nd nd ↑(58)ELISA (49)
60 75IHC No nd (53)
60 70IHC Yes ↑(60)ELISA (51)
Lung cancer 39 26IHC nd nd (56)
106 75IHC Yes nd (57)
101 41.6IHC nd ↑(91)ELISA (54)
nd nd nd ↑(137)ELISA (55)
nd nd nd ↑(43)ELISA (49)
Renal cell carcinoma 18 61IHC nd nd (59)
38 76qPCR nd nd (61)
(Continued)
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Table 1 | Continued
Tumor HLA-G molecule Reference
n Expression (%) Metastasisa sHLA-G (n)
Clear cell renal carcinoma 12 58IHC nd nd (60)
95 46.8IHC nd ↑(16)ELISA (62)
Glioblastoma 5 80IHC nd nd (63)
26 ≥58IHC nd nd (64)
39 64IHC nd nd (65)
108 60.2IHC nd nd (66)
Acute myeloid leukemia nd nd nd ↑(75)ELISA (78)
77 45FC nd nd (67)
22 68.2FC nd nd (68)
B-cell chronic lymphocytic leukemia 47 1–54FC nd nd (69)
20 1–34FC nd nd (72)
30 35.31FC nd nd (73)
aAssociation between HLA-G expression and metastasis.
sHLA-G, soluble HLA-G; IHC, imunohistochemistry; nd, not determined; (E), breast carcinoma effusions; (S), breast carcinoma solid lesions; ↑, increased sHLA-G
levels in patients; ELISA, enzyme-linked immunosorbent assay; WB, western blotting; Ø, similar sHLA-G levels between patients and controls; RT-PCR, reverse
transcriptase-PCR; qPCR, quantitative PCR; FC, flow cytometry.
POLYMORPHIC SITES AT HLA-G GENE AND TUMORS
Several isolated segments of the HLA-G gene have been studied in
tumors, highlighting the 3′ untranslated and coding regions. Cer-
tainly, the 14-bpINS/DEL polymorphism is the most studied. In
breast cancer patients, the 14-bpDEL allele and 14-bpDEL/DEL
genotype were associated with susceptibility to breast cancer
in Southeastern Iranian (80) and Korean patients (81); how-
ever, no association has been reported for Brazilians (26). In
addition, Korean patients exhibiting the 14-bpINS/INS genotype
exhibited no HLA-G expression in breast cancer lesions (81). A
meta-analysis evaluating the role of the 14-bpINS/DEL polymor-
phism in breast cancer reports an overall cancer risk in Asian
populations (82).
The 14-bpDEL allele was associated with susceptibility to hepa-
tocellular carcinoma in Brazilian (83) and Chinese (84) patients,
but not in Korean patients (84). In addition, Chinese patients
exhibiting the 14-bpDEL/DEL genotype presented increased HLA-
G expression in hepatocellular carcinoma specimens (84). The
14-bpINS/DEL genotype was associated with decreased risk for
childhood neuroblastoma development in Australian and New
Zealand patients (85). The HLA-G 3′UTR haplotype known as
UTR-3 (86) was associated with susceptibility to acute myeloid
leukemia development in Italian patients (68).
Considering the HLA-G coding segment, the +755C/A (non-
synonymous Leu/Ile substitution at codon 110, which defines
the HLA-G*01:04 protein group) was associated with protection
against more severe nasopharyngeal carcinoma tumor stages (87).
Regarding the bladder TCC, the HLA-G*01:04:04 allele, and
the HLA-G*01:04 allelic group were associated with susceptibil-
ity to bladder TCC in smoking patients and the HLA-G*01:03
allele and the HLA-G*01:04 allelic group was associated with
protection against bladder TCC development in non-smoking
Brazilian patients. In addition, the HLA-G*01:01 allelic group
and HLA-G*01:01/G*01:01 genotype were associated with sus-
ceptibility to bladder TCC development in non-smokers. Con-
sidering the bladder TCC progression, the following associa-
tions were observed: (i) the HLA-G*01:03 allele was associ-
ated with high-grade tumors among smokers; (ii) the HLA-
G*01:01:01/G*01:01:02 genotype was associated with protection
against high-grade tumors in the whole group of patients, whereas
the same association was observed with the HLA-G*01:01 group,
but only among smokers; and (iii) the HLA-G*01:04 allele group
was associated with high-grade tumor development in smoker and
in the whole group of patients (88).
No association has been observed for: (i) HLA-G coding region
alleles in South Korean and Brazilian breast cancer patients (81,
89); (ii) 14-bpINS/DEL polymorphism in Italian patients pre-
senting thyroid cancer (76); (iii) HLA-G*01:03 allele and HLA-
G*01:05N null allele in Tunisian patients with nasopharyngeal
carcinoma (87); (iv) HLA-G*01:05N null allele with suscepti-
bility to esophagus carcinoma development in Chinese patients
(90); (v) 14-bp INS/DEL polymorphic site in Brazilian bladder
TCC patients (88); and (vi) +292A/T, +755C/A, and +1799C/T
in Australian and New Zealand childhood neuroblastoma
patients (85).
To date, HLA-G polymorphisms have not been investigated in
the context of melanoma, glioblastoma, colorectal cancer, gastric
cancer, lung cancer, and renal cell carcinoma.
Although some polymorphic sites (14-bpDEL allele) and cod-
ing region allele groups (HLA-G*01:04) have been previously asso-
ciated with increased sHLA-G levels, few convincing associations
have been reported, exception made to breast cancer for which an
extensive meta-analysis has evidenced the role of this polymor-
phic site in Asiatic patients. Since several polymorphic sites have
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been described at the HLA-G regulatory regions, exhibiting puta-
tive roles on HLA-G expression, the typing of the complete gene
and the study of the regulatory elements (transcription factors and
microRNAs) produced in the tumor environment may the helpful
to understand the mechanisms of tumor evasion mechanisms.
VIRAL HEPATITIS
Similar to tumor cells, viruses have also developed several strate-
gies to evade the cytotoxic effect of immune effector cells, including
downregulation of HLA classical class I molecules and the upreg-
ulation of non-classical molecules, or both. As a corollary, the
increased HLA-G expression, induced by the virus itself or by the
presence of an inflammatory milieu containing transcription and
post-transcription factors that positively modulate HLA-G expres-
sion, may exacerbate virus morbidity and/or patient mortality. The
influence of HLA-G has been studied in several chronic viral infec-
tions; some of them associated with neoplastic transformation,
including human immunodeficiency virus (HIV), human papil-
lomavirus (HPV), human cytomegalovirus (hCMV), and hepatitis
viruses [reviewed at Ref. (2)].
Increased HLA-G hepatocyte expression in HCV-infected liver
specimens has been associated with milder stages of fibrosis and
hemosiderin deposit (91). Besides hepatocytes, HLA-G expres-
sion was observed on mast cells present in areas of liver fibrosis
(92). Increased plasma sHLA-G levels were associated with chronic
HCV infection and with increased IL-10 and IFN-γ levels (93).
Since the treatment of mast cells with IL-10 and class I interfer-
ons induces HLA-G expression (92), infiltrating cells may play
an important role on the maintenance of chronic infection and
induction of chronic complications.
One study has associated increased HLA-G expression in hepa-
tocytes with the HBV viral load (94). Different studies asso-
ciated the increased serum/plasma sHLA-G levels with hepati-
tis B virus infection (33, 95, 96), which were associated with
increased percentage of CD4+CD25+FoxP3+ T regulatory and
HLA-G+CD14+ monocytes cells in patients exhibiting acute or
chronic hepatitis (95), active hepatitis B virus infection (33) and
HBeAg negative hepatitis, hepatocellular carcinoma, and increased
alanine aminotransferase levels (96).
Regarding the typing of HLA-G 3′UTR polymorphic sites in
HCV- and HBV-infected patients, the +3142C allele and 14-
bpDEL/+3142C haplotype were underrepresented in Brazilian
HCV-infected patients presenting sickle cells disease compared
with HCV-negative group (97). On the other hand, the 14-
bpINS/INS genotype was overrepresented in African-Brazilian
HIV+ patients co-infected with HCV (HIV+/HCV+) compared
with HIV+/HCV− patients. Regarding the HLA-G+3142 C/G
and 14-bp INS/DEL variants, no significant association has been
reported for HIV+/HCV+- (98) and HBV-infected patients (99),
respectively, when compared with their respective controls.
Considering that many viruses have developed evasion strate-
gies that are similar to cancer cells and considering that many
chronic viral disorders have been associated with cell transforma-
tion and malignancy, the expression of HLA-G in these disorders




Plasmodium spp. is the etiologic agent of the human malaria and
little is known about the role of HLA-G during malaria infection,
and all studies have been performed to understand the mother
to child transmission. One study reported a decreased HLA-G
expression in extravillous trophoblast of Plasmodium falciparum-
infected placentas compared to uninfected placentas. If by one
hand, HLA-G molecule is almost exclusively expressed in extravil-
lous trophoblast of healthy placenta specimens, on the other hand,
HLA-G is detected in intervillous space macrophages of Plas-
modium-infected placentas. In addition, NK cells are increased
in infected compared to uninfected placentas (100). Furthermore,
increased cord plasma levels of sHLA-G have been associated with
low birth weight and increased risk of P. falciparum infection in
infancy (101).
A family based association study performed on individuals
from Niakhar, Senegal, reported that the +3187G allele was asso-
ciated with higher transmission to children and lower level of
parasite density during asymptomatic P. falciparum infection. The
HLA-G 3′UTR haplotype known as UTR-1 was associated with a
decreased level of parasite density during asymptomatic infection
under a dominant model, whereas the HLA-G UTR-3 haplotype
was associated with an increased level of parasite density during
the follow-up and increased intensity of asymptomatic infection
under a recessive model (102).
A second family based association study also conducted on
Senegalese population has tested the association of HLA-G 3′UTR
variants with acquired anti-malarial humoral immunity. The
+3010G and+3142C alleles were overtransmitted to children with
increased total IgG and IgG1 antibodies levels against glutamate-
rich protein (GLURP) of P. falciparum, and the +3196G allele
had a preferential transmission to children with a lower IgG3
response against merozoite surface protein 2 (MSP2). The HLA-
G 3′UTR-2 haplotype was associated with a decreased IgG3
response against MSP2, suggesting a role of HLA-G on the
regulation of immune humoral response during P. falciparum
infection (103).
HUMAN AFRICAN TRYPANOSOMIASIS
Human African trypanosomiasis, also known as sleeping sick-
ness, is caused by protozoan parasites of the Trypanosoma bru-
cei species. Although no studies are available regarding HLA-G
expression, genetic studies report associations of HLA-G gene
single nucleotide variation sites with the disease. A family based
association study reported that the HLA-G 3′UTR-14-bpINS and
+3196G alleles had a preferential transmission from heterozy-
gote parents to children and were associated with susceptibility to
human African trypanosomiasis (HAT) development. In contrast,
the HLA-G 3′UTR+3003C,+3010G, and+3187G alleles showed
lower transmission from parents to children and were associated
with decreased risk of developing the disease. Regarding HLA-G
3′UTR haplotypes, UTR-2 and UTR-5 haplotypes were associated
with higher susceptibility to HAT development, whereas the HLA-
G UTR-4 haplotype was associated with decreased risk for HAT
development (104).
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AMERICAN TRYPANOSOMIASIS
The parasite Trypanosoma cruzi is the etiologic agent of Ameri-
can trypanosomiasis, also known as Chagas disease (105). In the
chronic phase, four major clinical forms are observed: (i) car-
diac that presents progressive congestive heart failure, various
cardiac arrhythmias, thromboembolic events, and sudden death;
(ii) digestive that is characterized by clinical signs of megae-
sophagus, megacolon, or both; (iii) cardiodigestive that com-
prises clinical and pathological signs of cardiac and digestive
involvement; and (iv) indeterminate that develops without evi-
dent clinical and pathological signs (106). Recently, our group
reported a decreased HLA-G expression on cardiac muscle and
colonic cells in patients presenting cardiac or digestive clinical
variants, respectively. On the other hand, no significant differ-
ences were observed regarding HLA-G expression in the esophagus
of patients with digestive form when compared to non-chagasic
patients.
Furthermore, we evaluated the polymorphic sites at the HLA-
G 3′UTR region in Brazilian chagasic patients. The +3003T
allele and +3003TT and +3187GG genotypes were overrepre-
sented, whereas the +3003C allele and +3003CT, +3010GC,
and +3042GC genotypes were underrepresented in symptomatic
patients. In addition, the+3027CC and+3035CC genotypes, and
the +3027C and +3035C alleles were associated with the diges-
tive form of Chagas disease. Regarding HLA-G 3′UTR haplotypes,
decreased UTR-4 and UTR-7 frequencies were associated with
symptomatic patients and with the digestive form, respectively.
On the other hand, UTR-13 was associated with the indeterminate
variant and UTR-14 with the cardiac form (107).
Overall, studies on the association between HLA-G and para-
sitic disorders are still scarce and only the HLA-G 3′UTR has been
evaluated.
CONCLUSION
Considering the tolerogenic properties of HLA-G and consider-
ing the aphorism that the induced expression of HLA-G may
be detrimental in tumors and chronic viral infection, the overall
findings reported is this revision corroborates this idea. Notewor-
thy, is the induced expression of HLA-G on the surface of tumor
cells, which has been associated with greater tumor morbidity,
tumor progression, and spreading. In addition, in chronic viral
infections associated with pre-neoplastic and neoplastic transfor-
mation. On the other hand, the repression of HLA-G expression
is less well studied; i.e., the decreased expression of HLA-G in
organs or conditions in which a constitutive expression of the
molecule is expected. For instance, the decreased expression of
HLA-G (placentas of P. falciparum-infected mothers or heart and
colonic specimens of Chagas disease) has been associated with
morbidity of the chronic parasitic infection.
Studies on the association of the HLA-G gene with diseases
of diverse etiology have underestimated the myriad of polymor-
phic sites present at the various gene segments and have primarily
focused on the evaluation of one or few polymorphic sites, par-
ticularly at the 3′UTR. Considering that many polymorphic sites
along the HLA-G gene can be readily performed and analyzed,
and considering the relevant role of isolated polymorphic sites
or HLA-G haplotypes on HLA-G expression, HLA-G typing on
diseases should add an additional tool on the understanding of
the role of HLA-G on disease associations.
Theoretically, polymorphic sites observed along the coding
region may modify the encoded protein and consequently the
interaction with HLA-G receptors and the formation of HLA-
G dimers that may more efficiently bind to HLA-G receptors.
Thus, a particular allele and a particular molecule could pro-
vide susceptibility or protection against a disease development;
however, such associations have not been strong enough to be
considered a disease marker, as has been observed for the classi-
cal association between HLA-B27 and ankylosing spondylitis. On
the other hand, polymorphic sites observed along the HLA-G pro-
moter and 3′UTR gene segments may modify gene expression,
accounting for disease morbidity. Unfortunately, few polymor-
phic sites along regulatory regions have extensively been evaluated
regarding their function, and probably a combination of regula-
tory transcriptional and posttranscriptional elements may account
for the final HLA-G production. Therefore, a complete gene eval-
uation together with the availability of transcription and protein
profiles may provide light to the understanding of the mechanisms
of HLA-G induction or repression in a specific disorder.
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